References
- Case DE, Reeves PR. (1975). The disposition and metabolism of I.C.I. 58,834 (Viloxazine) in humans. Xenobiotica 5:113–29.
- Case DE, Illston H, Reeves PR, et al. (1975). The disposition and metabolism of LCI. 58,834 (ViloxazJne) in animals. Xenobiotica 5:83–111.
- FDA. (2016). Safety Testing of Drug Metabolites Guidance for Industry. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites
- Garcia-Olivares J, Schwabe S, Yu C. 2020. Effects of viloxazine on central neurotransmitter systems: a microdialysis study in freely moving rats. Presented at the American Society for Experimental Neurotherapeutics Annual Meeting; March 2–5; Bethesda, MD.
- Ghosh AK, Brindisi M. (2015). Organic carbamates in drug design and medicinal chemistry. J Med Chem 58:2895–940.
- Gibbs JP, Hyland R, Youdim K. (2006). Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism. Drug Metab Dispos 34:1516–22.
- Gunduz M, Argikar UA, Baeschlin D, et al. (2010). Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies. Drug Metab Dispos 38:361–7.
- Gunduz M, Argikar UA, Cirello AL, Dumouchel JL. (2018). New perspectives on acyl glucuronide risk assessment in drug discovery: investigation of in vitro stability, in situ reactivity, and bioactivation. Drug Metab Lett 12:84–92.
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13.
- ICH. (2010). Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/m3r2-nonclinical-safety-studies-conduct-human-clinical-trials-and-marketing-authorization
- INTUNIV®. (2019). Prescribing information. Lexington, MA. Shire US Inc. Available from: https://www.shirecontent.com/PI/PDFS/Intuniv_USA_ENG.pdf
- KAPVAY®. (2017). Prescribing information. St. Michael, Barbados. Concordia Pharmaceuticals Inc. Available from: https://www.lupin.com/US/pdf/18/02/clonidine-hcl-er-tabs-kapvay-pi-11-2017.pdf
- Laaban JP, Dupeyron JP, Lafay M, et al. (1986). Theophylline intoxication following viloxazine induced decrease in clearance. Eur J Clin Pharmacol 30:351–3.
- Obach RS, Cox LM, Tremaine LM. (2005). Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33:262–70.
- Pinder RM, Brogden RN, Speight TM, Avery GS. (1977). Viloxazine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 13:401–21.
- Pisani F, Fazio A, Oteri G, et al. (1986). Carbamazepine-viloxazine interaction in patients with epilepsy. J Neurol Neurosurg Psychiat 49:1142–5.
- Sadeque AJM, Usmani KA, Palamar S, et al. (2012). Identification of human UDP-glucuronosyltransferases involved in N-carbamoyl glucuronidation of lorcaserin. Drug Metab Dispos 40:772–8.
- Schaefer WH. (2006). Reaction of primary and secondary amines to form carbamic acid glucuronides. Curr Drug Metab 7:873–81.
- STRATTERA®. (2017). Prescribing information. Indianapolis, IN: Lilly USA, LLC.
- Vincent SH, Reed JR, Bergman AJ, et al. (2007). Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35:533–8.